Clinical trials: Hormone Refractory
Prostatic Neoplasms
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
Primary objectives: To determine the response rate, measurable and non measurable, to Taxotere® in the second line setting. Secondary objectives: To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as…
- Trial name
- NCT00268710
- Testing
- docetaxel
- Sponsor
- Sanofi
Prostate Cancer
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of…
- Trial name
- NCT00519233
- Testing
- AGS-1C4D4
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have…
- Trial name
- NCT00089856
- Testing
- Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone)
- Where
- 126 sites in United States, Belgium and 6 more
- Volunteers
- 626 people
- Sponsor
- Cell Genesys
Prostatic Neoplasms
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in…
- Trial name
- NCT00473512
- Testing
- Abiraterone acetate, Abiraterone acetate MTD, Dexamethasone
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Cougar Biotechnology, Inc.
Therapy, Prostatic Neoplasms
Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the safety of docetaxel administered every 3 weeks repeatedly for 11 and more cycles and in combination with daily prednisolone for metastatic hormone refractory prostate cancer.
- Trial name
- NCT00723086
- Testing
- docetaxel (XRP6976)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Sanofi
Prostatic Neoplasms
MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)
This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.
- Trial name
- NCT00302471
- Testing
- Comparator: MK0429
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Hormone Refractory Prostate Cancer
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given…
- Trial name
- NCT00477529
- Testing
- ABI-008
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Celgene
Breast Neoplasms
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Progression-free rate after 16 weeks of BIBW 2992 administration in association with letrozole
- Trial name
- NCT00708214
- Testing
- BIBW 2992, Letrozole
- Where
- 5 sites in France
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Lung Cancer
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
The purpose of this study is to test the combination of an experimental drug known as MGCD0103 given along with an FDA-approved drug called docetaxel.
- Conditions
- Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT00511576
- Testing
- MGCD0103 & Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Mirati Therapeutics Inc.
Prostatic Neoplasms
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate…
- Trial name
- NCT00401765
- Testing
- CNTO 328, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Centocor, Inc.
Metastatic Hormone Refractory Prostate Cancer
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer.
- Trial name
- NCT00411528
- Testing
- Patupilone, prednisone, docetaxel
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either…
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00950911
- Testing
- amg 162
- Where
- 17 sites in Czechia, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Amgen
Hormone-Refractory Prostate Cancer
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
This is a randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen-loaded dendritic cells (Provenge, APC8015) for asymptomatic, metastatic, hormone-refractory prostate cancer.
- Trial name
- NCT01133704
- Testing
- sipuleucel-T
- Volunteers
- 98 people
- Sponsor
- Dendreon
Sarcoma, Castrate Resistant Prostate Cancer
A Study of PRT2527 in Participants With Advanced Solid Tumors
This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors.
- Conditions
- Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05159518
- Testing
- PRT2527
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Prelude Therapeutics Incorporated
Breast Cancer
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with letrozole (Femara) and of XL765 when given in combination with letrozole.
- Trial name
- NCT01082068
- Testing
- XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara)
- Where
- 17 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- Sanofi
Neoplasms, Prostatic Neoplasms
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously…
- Trial name
- TROPIC (NCT00417079)
- Testing
- cabazitaxel (XRP6258) (RPR116258), mitoxantrone, prednisone
- Where
- 26 sites in United States, Argentina and 24 more
- Volunteers
- 755 people
- Sponsor
- Sanofi
Prostate Cancer
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
This Phase II single dose study was designed to characterize the safety, tolerability, and efficacy of intravenous (i.v.) panobinostat as a single-agent treatment in participants with hormone refractory prostate cancer.
- Trial name
- NCT00667862
- Testing
- Panobinostat
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters)…
- Conditions
- Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT01487863
- Testing
- sipuleucel-T, abiraterone acetate
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Dendreon
Prostate Cancer, Neoplasm Metastasis
BAY88-8223, Dose Finding Study in Patients With HRPC
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00337155
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- United Kingdom
- Volunteers
- 122 people
- Sponsor
- Bayer
Prostate Cancer
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
- Trial name
- NCT00036543
- Testing
- Atrasentan
- Where
- 232 sites in United States, Australia and 16 more
- Volunteers
- 1,000 people
- Sponsor
- Abbott